Your browser doesn't support javascript.
loading
The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
Engels, Charla C; Kiderlen, Mandy; Bastiaannet, Esther; van Eijk, Ronald; Mooyaart, Antien; Smit, Vincent T H B M; de Craen, Anton J M; Kuppen, Peter J K; Kroep, Judith R; van de Velde, Cornelis J H; Liefers, Gerrit Jan.
Afiliação
  • Engels CC; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
  • Kiderlen M; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands. m.kiderlen@lumc.nl.
  • Bastiaannet E; Department of Geriatrics and Gerontology, Leiden University Medical Center, Leiden, The Netherlands. m.kiderlen@lumc.nl.
  • van Eijk R; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
  • Mooyaart A; Department of Geriatrics and Gerontology, Leiden University Medical Center, Leiden, The Netherlands.
  • Smit VT; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Craen AJ; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Kuppen PJ; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Kroep JR; Department of Geriatrics and Gerontology, Leiden University Medical Center, Leiden, The Netherlands.
  • van de Velde CJ; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
  • Liefers GJ; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Breast Cancer Res Treat ; 156(2): 361-70, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26968397
Studies to confirm the effect of acknowledged prognostic markers in older breast cancer patients are scarce. The aim of this study was to evaluate the prognostic value of HER-2 overexpression and PIK3CA mutations in older breast cancer patients. Female breast cancer patients aged 65 years or older, diagnosed between 1997 and 2004 in a geographical region in The Netherlands, with an invasive, non-metastatic tumour and tumour material available, were included in the study. The primary endpoint was relapse-free period and secondary endpoint was relative survival. Determinants were immunochemical HER-2 scores (0/1+, 2+ or 3+) and PIK3CA as a binary measure. Overall, 1698 patients were included, and 103 had a HER-2 score of 3+. HER-2 overexpression was associated with a higher recurrence risk (5 years recurrence risk 34 % vs. 12 %, adjusted p = 0.005), and a worse relative survival (10 years relative survival 48 % vs. 84 % for HER-2 negative; p = 0.004). PIK3CA mutations had no significant prognostic effect. We showed, in older breast cancer patients, that HER-2 overexpression was significantly associated with a worse outcome, but PIK3CA mutations had no prognostic effect. These results imply that older patients with HER-2 overexpressing breast cancer might benefit from additional targeted anti-HER-2 therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Regulação para Cima / Receptor ErbB-2 / Fosfatidilinositol 3-Quinases / Mutação Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Regulação para Cima / Receptor ErbB-2 / Fosfatidilinositol 3-Quinases / Mutação Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article